A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

Summary

This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.

Timeline

Start

2023-11

Primary completion

2024-06

Completion

2026-07

Drugs

Indications